Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease V: Interprofessional Care
Dhruv S Kazi1, Andrew E Moran2, Pamela G Coxson3
1Department of Medicine, Center for Vulnerable Populations, University of California, San Francisco2Department of Medicine, University of California, San Francisco3Department of Epidemiology and Biostatistics, University of California, San Francisco4Center.

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
10:56A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
在PubMed 上查看摘要
在目前的价格下,治疗家族性高胆固醇血症 (FH) 和动脉样性心血管疾病 (ASCVD) 的PCSK9抑制剂不具有成本效益. 需要大幅降低药品成本以达到成本效益的门,避免增加美国的整体医疗支出.
科学领域:
背景情况:
研究的目的:
主要方法:
主要成果:
结论: